ARCAPTA NEOHALER
LOE ApproachingNDAINHALATIONPOWDER
Approved
Jul 2011
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
2/8 — Basic
Drug data last refreshed 37m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ARCAPTA NEOHALER is an inhalation powder formulation approved in 2011 as a small molecule therapeutic. The specific indication and mechanism of action are not available in current data, but the delivery via dry powder inhaler suggests a respiratory or systemic condition requiring lung administration. This is a Novartis-sponsored product in the NDA category.
LOE Approaching1.9 years to LOE
Approaching loss of exclusivity in 2028 suggests moderate-to-declining team size and shift in focus from growth to transition planning and generics preparation.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Patent cliff in ~2 years — expect lifecycle management and generic defense hiring
Worked on ARCAPTA NEOHALER at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.